Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP2 + nivolumab
- Development stage
- Unknown
- Lead developer
- Replimune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
**RP2 + nivolumab** is an investigational combination therapy of a genetically modified oncolytic herpes simplex virus type 1 (HSV-1) known as RP2 and the immune checkpoint inhibitor nivolumab (a PD-1 blocking antibody). RP2 is engineered to directly destroy tumor cells and express an anti-CTLA-4 antibody within the tumor microenvironment to stimulate anti-tumor immune responses. Nivolumab blocks PD-1 to enhance T-cell activity against cancer. The combination aims to synergistically increase anti-tumor immunity, particularly in advanced, metastatic, and immune checkpoint inhibitor-naïve solid tumors, including metastatic uveal melanoma. RP2 is administered via intratumoral injection, and nivolumab via intravenous infusion. The combination is being studied in phase 1 and phase 2/3 clinical trials for various solid tumors, especially metastatic uveal melanoma[1][2][3][4][6][8].
- Brand names
- OPDIVO
- Other names
- RP2 and nivolumabRP-2 and nivolumabRP 2 and nivolumabRP2 in combination with nivolumabRP-2 in combination with nivolumabRP 2 in combination with nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on RP2 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP2 + nivolumab.